value proposition to health and medical companies is highly
tangible and quantifiable, empowering such things as patent
life extensions on leading injectable drugs; providing â€˜painlessâ€™
marketing differentiation for intramuscular and subcutaneous
injectable treatments; and perhaps, most important, helping
to drive greater patient compliance, thus improving quality
of life for patients requiring injectable drugs while promoting
greater revenue growth for the companies that produce them.
is currently seeking to establish strategic collaborations
with companies interested in exploring opportunities to develop
new disruptive drug delivery technologies that will enable
them to raise the barriers to market entry and differentiate
their drug products from those delivered by otherwise conventional
Milestone anticipates that
any application for a device developed utilizing the CompuFlo system will require 510(k) approval from the FDA, which should
reduce development cost and time to market.